Trial Profile
Predictability of response of aflibercept treatment for wet age-related macular degeneration under the treat-and-moderate extend regimen (TMER) treatment model
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Feb 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 10 Apr 2020 Status changed from recruiting to completed.
- 10 Apr 2020 Results published in the Advances in Therapy
- 08 Dec 2015 New trial record